Novo Nordisk A/S $NVO Shares Sold by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 23.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,610 shares of the company’s stock after selling 9,899 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $2,182,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AE Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 20.8% in the first quarter. AE Wealth Management LLC now owns 5,742 shares of the company’s stock worth $399,000 after acquiring an additional 989 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Novo Nordisk A/S in the first quarter worth about $41,000. LPL Financial LLC boosted its holdings in Novo Nordisk A/S by 1.7% in the first quarter. LPL Financial LLC now owns 1,379,207 shares of the company’s stock valued at $95,643,000 after purchasing an additional 23,140 shares during the last quarter. Finally, N.E.W. Advisory Services LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at approximately $106,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and cut their target price for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $57.40.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $48.75 on Thursday. The firm’s 50 day moving average is $53.32 and its two-hundred day moving average is $59.93. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $217.67 billion, a P/E ratio of 13.39, a PEG ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.